Univariate analyses of graft cell dose (≥ vs < 50th percentile) for donor engraftment, graft-versus-host disease, and survival
. | P (RR [95% Cl])* . | . | . | . | |||
|---|---|---|---|---|---|---|---|
. | CD34+ T-cell dose . | CD3+ T-cell dose . | CD4+ T-cell dose . | CD8+ T-cell dose . | |||
| Full (at least 95%) donor engraftment† | |||||||
| Blood CD3+ | .52 (0.8 [0.4-1.6]) | .35 (1.4 [0.7-2.8]) | .71 (0.9 [0.4-1.7]) | .03 (2.2 [1.1-4.7]) | |||
| Blood CD15+ | .85 (1.0 [0.5-1.6]) | .08 (1.7 [0.9-3.0]) | .08 (1.7 [0.9-3.0]) | .15 (1.5 [0.9-2.7]) | |||
| Graft-versus-host disease | |||||||
| Acute GVHD, grade II-IV | .07 (0.2 [0.1-1.1]) | .15 (0.4 [0.1-1.4]) | .95 (1.0 [0.3-3.3]) | .13 (0.4 [0.1-1.4]) | |||
| Chronic GVHD, extensive | .84 (0.9 [0.4-2.2]) | .67 (0.8 [0.3-2.0]) | .84 (0.9 [0.4-2.2]) | .26 (1.7 [0.7-4.5]) | |||
| Survival | |||||||
| Freedom from progression | .64 (0.8 [0.4-1.9]) | .19 (0.6 [0.3-1.3]) | 0.81 (0.9 [0.4-2.1]) | .001 (0.2 [0.1-0.5]) | |||
| Overall survival | .86 (0.9 [0.5-1.8]) | .06 (0.5 [0.3-1.0]) | .40 (0.8 [0.4-1.5]) | .03 (0.5 [0.3-0.9]) | |||
. | P (RR [95% Cl])* . | . | . | . | |||
|---|---|---|---|---|---|---|---|
. | CD34+ T-cell dose . | CD3+ T-cell dose . | CD4+ T-cell dose . | CD8+ T-cell dose . | |||
| Full (at least 95%) donor engraftment† | |||||||
| Blood CD3+ | .52 (0.8 [0.4-1.6]) | .35 (1.4 [0.7-2.8]) | .71 (0.9 [0.4-1.7]) | .03 (2.2 [1.1-4.7]) | |||
| Blood CD15+ | .85 (1.0 [0.5-1.6]) | .08 (1.7 [0.9-3.0]) | .08 (1.7 [0.9-3.0]) | .15 (1.5 [0.9-2.7]) | |||
| Graft-versus-host disease | |||||||
| Acute GVHD, grade II-IV | .07 (0.2 [0.1-1.1]) | .15 (0.4 [0.1-1.4]) | .95 (1.0 [0.3-3.3]) | .13 (0.4 [0.1-1.4]) | |||
| Chronic GVHD, extensive | .84 (0.9 [0.4-2.2]) | .67 (0.8 [0.3-2.0]) | .84 (0.9 [0.4-2.2]) | .26 (1.7 [0.7-4.5]) | |||
| Survival | |||||||
| Freedom from progression | .64 (0.8 [0.4-1.9]) | .19 (0.6 [0.3-1.3]) | 0.81 (0.9 [0.4-2.1]) | .001 (0.2 [0.1-0.5]) | |||
| Overall survival | .86 (0.9 [0.5-1.8]) | .06 (0.5 [0.3-1.0]) | .40 (0.8 [0.4-1.5]) | .03 (0.5 [0.3-0.9]) | |||
GVHD indicates graft-versus-host disease.
Risk ratio value indicates likelihood, respectively, of full donor engraftment, graft-versus-host disease, death (overall survival), or death and/or disease progression (progression-free survival) with higher G-PBMC cell dose
Five patients were not evaluable for donor engraftment. Analyses represent correlation between cell doses and donor engraftment in the remaining 58 patients